Yep jessieYou are getting the picture. Heres something old but...

Yep jessie

You are getting the picture.

Heres something old but interesting from PC. From only a few months ago. Seems like a lifetime.



''Openbriefing.com
Biota Holdings Limited today reported NPAT of $33.5 million for the first half ended December 2009, up from $7.2 million for the previous corresponding period. If earnings are maintained at this level in the current second half, youd book NPAT of over $65 million for the full year ending June 2010, up from $38 million last year. Would this be a reasonable expectation? To what extent is this indicative of the likely level of earnings going forward? ''

''CEO Peter Cook
Based on the first half alone well have a record year. Were very pleased with the progress weve made and the impetus the first half gives us for the full year.

However, were not prepared to provide full-year guidance given GlaxoSmithKline (GSK) has control over the sale and delivery process for Relenza, the main source of our royalty income. No-one, not even GSK customers buying Relenza, can forecast the course of the current influenza pandemic. Well continue to update the market quarterly on our indicative Relenza royalties, which we expect to remain solid.




''Openbriefing.com
Bridging Western early phase clinical studies with laninamivir, funded by the US National Institutes of Health, were also completed in the first half. Its your intention to secure a licensee for laninamivir outside Japan in the near future. Will you need to complete further bridging studies before securing a partner?

CEO Peter Cook
Weve indicated its our intention to seek a rest-of-the-world licensee for laninamivir in the near future. Were pleased with the level of interest being shown in the product, and the diversity of interested parties. Any rest-of-the-world licensee would have to undertake further clinical studies before approval is likely in Western markets. Whether these are undertaken by the licensee or ourselves will be a matter of timing and practicality and the terms of any licensing agreement''


http://www.bioinvest.com.au/news/view/91